Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study

Author:De Stefano, Nicola   Achiron, Anat   Barkhof, Frederik   Chan, Andrew   Derfuss, Tobias   Hodgkinson, Suzanne   Leocani, Letizia   Montalban, Xavier   Prat, Alexandre   Schmierer, Klaus   Sellebjerg, Finn   Vermersch, Patrick   Wiendl, Heinz   Keller, Birgit   Smyk, Andrzej   Gardner, Lidia   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.018  

Author Institution:Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy  Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel  Department of Radiology, VU University Medical Center, Amsterdam, Netherlands  Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  Department of Neurology, University Hospital Basel, Basel, Switzerland  Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia  Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy  Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain  Department of Neurosciences, Université de Montréal, Montreal, QC, Canada  The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom  Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark  Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  Department of Neurology, Institute of Translational Neurology, University of Münster, Muenster, Germany  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  EMD Serono Research and Development Institute, Inc., Billerica, MA, USA , Billerica, MA  

Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study

Author:Bermel, Robert   Killestein, Joep   Berger, Thomas   Brochet, Bruno   Carroll, William   Freedman, Mark   Holmoy, Trygve   Karabudak, Rana   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Vollmer, Timothy   Buffels, Regine   Kadner, Karen   Bortolami, Oscar   Hartung, Hans-Peter   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.003  

Author Institution:Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria  University of Bordeaux, Bordeaux, France, Bordeaux, France  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Ottawa, ON, Canada  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Centre d’Esclerosi Mútiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA , Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Toulon, France  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Department of Neurology, UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Dusseldorf, Germany  

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Author:Williams, Mitzi   Airas, Laura   Chitnis, Tanuja   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Dörner, Thomas   Loop, Brett   Ziehn, Marina   Willi, Roman   Kieseier, Bernd C.   Nikolaev, Ivan   Haemmerle, Sibylle   Zharkov, Artem   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Giménez-Arnau, Ana   Montalban, Xavier   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.015  

Author Institution:Joi Life Wellness Group, Atlanta, GA, USA, Atlanta, GA  Turku University Hospital and University, Finland, Turku, Finland  Brigham and Women's Hospital, Department of Neurology, Boston, MA, USA, Boston, MA  Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA, Baltimore, MD  Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, Hiroshima, Japan  University of Toronto, Toronto, Ontario, Canada, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin  DRFZ, Berlin, Germany, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA, USA, Cambridge, MA  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Heinrich-Heine University, Duesseldorf, Germany, Duesseldorf, Germany  Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany  Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, Berlin, Germany  Department of Dermatology, Hospital del Mar - IMIM, Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  

Pregnancy Outcomes in Patients With MS Following Exposure to Ofatumumab: Updated Results From the Novartis Safety Database

Author:Bove, Riley   Pia Amato, Maria   Dobson, Ruth   M. Krysko, Kristen   Stoll, Sharon   Vukusic, Sandra   Yamout, Bassem   Zielman, Ronald   Krishna Gummuluri, Swetha   Jehl, Valentine   Schulze Topphoff, Ulf   Sullivan, Roseanne   Fantaccini, Simone   Hellwig, Kerstin   

Session Name:P9: MS Special Populations  

Topic:MS and Inflammatory Disease  

Program Number:P9.014  

Author Institution:UCSF Weill Institute for Neuroscience, University of California San Francisco, San Francisco, California, USA, Berkeley, CA  Department NEUROFARBA, University of Florence, Florence, Italy  IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy, Florence, Italy  Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom  Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom, London, United Kingdom  Division of Neurology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada  Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada, Toronto, ON, Canada  Department of Neurology, Yale University, New Haven, Connecticut, USA, New Haven, CT  Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France  Centre des Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques, Lyon, France  Université Claude Bernard Lyon 1, Villeurbanne, France, BRON Cedex, France  American University of Beirut Medical Center, Beirut, Lebanon  Harley Street Medical Centre, Abu Dhabi, UAE, Beirut, Lebanon  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India  Novartis Pharma A.G. Basel, Switzerland, Basel, Switzerland  Novartis Pharma GmbH, Germany, Nuernberg, Germany  Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ  Novartis Pharma A.G. Basel, Switzerland, Binningen, Switzerland  St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany, Bochum, Germany